Notice

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea​

2018.06.05

 

Executive Summary

Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy. 

 

by Jung Won Shin (Jungwon.Shin@informa.com)


scrippharmaintelligence https://scrip.pharmaintelligence.informa.com/SC123167/Interview-KoBioLabs-Pioneering-The-Microbiome-Landscape-In-Korea

 

Back to List
Top